Skip to main content

Lactobacillus helveticus R0052 alleviates liver injury by modulating gut microbiome and metabolome in d-galactosamine-treated rats

  • 2019-11-12
  • Applied Microbiology and Biotechnology 103(23-24)
    • Qiangqiang Wang
    • L. Lv
    • Huiyong Jiang
    • Kaicen Wang
    • Ren Yan
    • Yating Li
    • Jianzhong Ye
    • Jingjing Wu
    • Qing Wang
    • Xiaoyuan Bian
    • Liya Yang
    • Xianwan Jiang
    • Jiaojiao Xie
    • Yanmeng Lu
    • Jian Shen
    • Lanjuan Li

Abstract

The liver is an important digestive gland, and acute liver failure results in high mortality. Probiotics are considered potential adjuvant therapies for liver disease. This study aimed to investigate the beneficial effects of Lactobacillus helveticus R0052 on acute liver injury and the underlying mechanisms. Sprague-Dawley rats were gavaged with L. helveticus R0052 suspensions (3 × 109 CFU) for 1 week. Subsequently, acute liver injury was induced by intraperitoneal D-galactosamine injection on the eighth day. After 24 h, samples (blood, liver, ileum, faeces) were collected and assessed for histological injury, inflammation, intestinal barrier, gut microbiome and metabolome. L. helveticus R0052 alleviated aminotransferase, bilirubin and total bile acid elevation and histological hepatic injuries. Additionally, L. helveticus R0052 exhibited anti-inflammatory properties by downregulating Toll-like receptors, tumour necrosis factor-α and nuclear factor-κb transcription in liver samples and decreasing proinflammatory cytokine plasma concentrations. Additionally, L. helveticus R0052 ameliorated intestinal abnormalities and regulated Toll-like receptors, claudin2 and mucin3 gene transcription in the intestine. These effects were associated with gut microbiome and metabolome modulation by L. helveticus R0052. Probiotic pretreatment enriched Lactobacillus and Bacteroides and depleted Flavonifractor and Acetatifactor in the gut microbiome. Meanwhile, L. helveticus R0052 improved carbohydrate and fatty acid metabolism and reduced lithocholic acid levels. These results indicate that L. helveticus R0052 is promising for alleviating acute liver injury and provide new insights regarding the correlations among the microbiome, the metabolome, the intestinal barrier and liver disease.

Keywords: Acute liver injury; Gut microbiome; Lactobacillus helveticus R0052; Metabolome.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus helveticusImproved Gastrointestinal HealthBeneficial
Moderate
Lactobacillus helveticusImproved Gut MicrobiomeBeneficial
Moderate
Lactobacillus helveticusReduced Histological Liver InjuryBeneficial
Moderate
Lactobacillus helveticusReduced Inflammation LevelsBeneficial
Moderate
Lactobacillus helveticus HA-501Alleviated Liver InjuryBeneficial
Large
Lactobacillus helveticus HA-501Improved Gastrointestinal HealthBeneficial
Moderate
Lactobacillus helveticus HA-501Improved Gut MicrobiomeBeneficial
Moderate
Lactobacillus helveticus HA-501Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus helveticus LH76Improved Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus helveticus LH76Improved Intestinal FunctionBeneficial
Moderate
Lactobacillus helveticus LH76Improved Liver FunctionBeneficial
Moderate
Lactobacillus helveticus LH76Improved Metabolic FunctionBeneficial
Moderate
Lactobacillus helveticus LH76Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus helveticus R0052Improved Gut MicrobiomeBeneficial
Moderate
Lactobacillus helveticus R0052Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus helveticus R0052Improved Metabolome ProfileBeneficial
Moderate
Lactobacillus helveticus R0052Reduced Hepatic Histological InjuryBeneficial
Moderate
Lactobacillus helveticus R0052Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus helveticus R0052Reduced Liver Enzyme LevelsBeneficial
Moderate
Lactobacillus helveticus Rosell-52Improved Gastrointestinal HealthBeneficial
Moderate
Lactobacillus helveticus Rosell-52Improved Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus helveticus Rosell-52Improved Metabolic HealthBeneficial
Moderate
Lactobacillus helveticus Rosell-52Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus helveticus Rosell-52Reduced Liver Injury IndicatorsBeneficial
Large
Lactobacillus helveticus Rosell-52 MEImproved Gut MicrobiomeBeneficial
Moderate
Lactobacillus helveticus Rosell-52 MEImproved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus helveticus Rosell-52 MEReduced Aminotransferase LevelsBeneficial
Moderate
Lactobacillus helveticus Rosell-52 MEReduced Bilirubin LevelsBeneficial
Moderate
Lactobacillus helveticus Rosell-52 MEReduced Liver InflammationBeneficial
Moderate
Lactobacillus helveticus Rosell-52 MEReduced Total Bile Acid LevelsBeneficial
Moderate
Lactobacillus helveticus Rosell-52NDImproved Gastrointestinal HealthBeneficial
Moderate
Lactobacillus helveticus Rosell-52NDImproved Gut MicrobiomeBeneficial
Moderate
Lactobacillus helveticus Rosell-52NDReduced InflammationBeneficial
Moderate
Lactobacillus helveticus VPro 13Alleviated Liver InjuryBeneficial
Large
Lactobacillus helveticus VPro 13Improved Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus helveticus VPro 13Improved Intestinal FunctionBeneficial
Moderate
Lactobacillus helveticus VPro 13Reduced Inflammation LevelsBeneficial
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.